Government of Canada orders smallpox vaccine from Bavarian Nordic  

2008.12.03
The Canadian government has procured 20,000 doses of Imvamune smallpox vaccine from Bavarian Nordic as part of the country's bio-preparedness programme
Danish biotechnology company Bavarian Nordic has announced in a press release that the Canadian government has procured 20,000 doses of Imvamune smallpox vaccine as part of the country's bio-preparedness programme.
 
The contract also contains an option to purchase a further 180,000 doses of the vaccine, as well as payment for investigating requirements for obtaining a licence of the vaccine in Canada.
 
”With the Canadian contract, yet another nation recognizes Imvamune as an essential part of the its smallpox preparedness," writes Bavarian Nordic CEO Anders Hedegaard in the press release. "This further demonstrates that countries are increasingly focused on building and retaining an optimum biological preparedness against smallpox, the world’s most feared and dangerous infectious disease."
 
Headquartered in Denmark, Bavarian Nordic develops, produces and markets innovative vaccines to prevent and treat infectious diseases such as smallpox, HIV and cancer. The company employs over 200 people and has operations in Germany, the US and Singapore. Bavarian Nordic has state-of-the-art production facilities in Denmark, and an ongoing partnership with the German vaccine producer, Impfstoffwerk Dessau-Tornau.
 
Link > Bavarian Nordic          

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×